Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences

Keryx Biopharmaceuticals Announces Participation at Upcoming Investor
Conferences

NEW YORK, Feb. 26, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive
Officer, will be presenting at the following upcoming healthcare investor
conferences:

34^TH Annual Cowen and Company Health Care Conference (Boston, MA)

Presentation Date: Monday, March 3^rd, 2014
Presentation Time: 2:50 pm ET

26^th Annual ROTH Conference (Dana Point, CA)

Presentation Date: Monday, March 10^th, 2014
Presentation Time: 12:00 Noon PT (3:00pm ET)

Live audio webcasts of these presentations will be accessible within the
Investor Relations section of the Company's Website at
http://www.keryx.com/webcasts-presentations. An archived version of each
webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of pharmaceutical products for the treatment of renal
disease. Keryx is developing ZerenexTM (ferric citrate coordination complex),
an oral, ferric iron-based compound. Zerenex has completed a U.S.-based Phase
3 clinical program for the treatment of hyperphosphatemia (elevated phosphate
levels) in patients with chronic kidney disease on dialysis, conducted
pursuant to a Special Protocol Assessment (SPA) agreement with the FDA.
Keryx's New Drug Application (NDA), submitted to the FDA in 2013, is currently
under review and has an assigned Prescription Drug User Fee Act (PDUFA) goal
date of June 7, 2014. The Marketing Authorization Application (MAA) filing
with the European Medicines Agency (EMA) is pending. Zerenex has also
completed a Phase 2 study in the U.S. for the management of elevated serum
phosphorus levels and iron deficiency anemia in patients with Stage 3 to 5
non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese
partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd., received
marketing approval of ferric citrate in Japan for the treatment of
hyperphosphatemia in patients with chronic kidney disease on January 17, 2014.
Keryx is headquartered in New York City.

CONTACT: KERYX CONTACT:
         Lauren Fischer
         Director - Investor Relations
         Keryx Biopharmaceuticals, Inc.
         Tel: 212.531.5965
         E-mail: lfischer@keryx.com

Keryx Logo
 
Press spacebar to pause and continue. Press esc to stop.